UBS Group Issues Positive Forecast for Zimmer Biomet (NYSE:ZBH) Stock Price

Zimmer Biomet (NYSE:ZBH) had its target price boosted by UBS Group from $120.00 to $130.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. UBS Group‘s target price suggests a potential upside of 21.41% from the stock’s current price.

ZBH has been the subject of several other research reports. Sanford C. Bernstein increased their target price on Zimmer Biomet from $93.00 to $107.00 and gave the stock a “market perform” rating in a research report on Thursday. Jefferies Financial Group reiterated a “hold” rating and set a $120.00 price target on shares of Zimmer Biomet in a report on Wednesday. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Canaccord Genuity Group boosted their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Finally, Robert W. Baird set a $104.00 target price on Zimmer Biomet in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $111.95.

Zimmer Biomet Trading Down 2.8%

ZBH stock traded down $3.07 on Thursday, reaching $107.08. The company’s stock had a trading volume of 3,623,755 shares, compared to its average volume of 2,266,789. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $112.54. The firm has a market cap of $20.42 billion, a PE ratio of 26.05, a PEG ratio of 2.33 and a beta of 0.50. The business has a fifty day simple moving average of $95.01 and a two-hundred day simple moving average of $91.99.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, research analysts forecast that Zimmer Biomet will post 8.54 EPS for the current year.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. Insiders own 1.28% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Tacita Capital Inc bought a new stake in shares of Zimmer Biomet during the second quarter worth $26,000. Ancora Advisors LLC bought a new position in Zimmer Biomet in the second quarter worth approximately $29,000. Elevation Wealth Partners LLC lifted its stake in shares of Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $44,000. Finally, Parvin Asset Management LLC purchased a new position in Zimmer Biomet in the second quarter worth $47,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, while adjusted EPS of $1.90 topped estimates of $1.88. The company also raised its full-year 2026 outlook; stronger hips and S.E.T. sales helped offset knee-market weakness. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its target to $125 and upgraded ZBH to “outperform,” providing a bullish signal. Royal Bank of Canada recommendations
• Neutral Sentiment: Citigroup lifted its target to $117 but kept a “neutral” rating. Wells Fargo raised its target to $113 and maintained “equal weight.” Citigroup recommendations Wells Fargo recommendations
• Negative Sentiment: Reported diluted EPS fell 13.8% to $1.00, while adjusted EPS was flat year over year. Knee weakness and margin pressure remain concerns; Bernstein raised its target to $107 but kept a “market perform” rating. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.